TiHKAL: The Continuation
The 1997 companion to PiHKAL, covering 55 tryptamines in the same two-part form: a narrative section, then a synthesis-and-commentary section built around the authors' own bioassays.
For this corpus it functions the way PiHKAL does — as the only published human data for a large number of compounds that were never studied clinically. Where a tryptamine page cites a duration, a qualitative character, or a threshold observation and the source is a self-experiment rather than a trial, this is usually the source.
What it claims
That a named compound produced a described set of effects, over a described time course, in a small number of self-experiments. It does not claim population-level dose-response, safety margins, or interaction behaviour, and it was not designed to.
How well attested
Weak by clinical standards and openly so. Sample sizes are one to a few, subjects were unblinded and knew what they had taken, and the observations are the authors' own. What makes it usable is that the method is stated rather than concealed: a reader can see exactly how thin the evidence is. Where a later controlled study exists, it supersedes this — the substance record says which.
Cited by
6 substance records cite this source